MoonLake Immunotherapeutics (MLTX) Stock Forecast
MLTX analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.13 / 5 from 15 analysts
- Price target
- $28.54 average of analyst targets
- Upside to target
- +198.8% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.77
- 52-week range
- $9.16 – $22.16
MLTX analyst ratings
15 analystsNumber of analysts at each rating.
MLTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MLTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.78 | −$0.88 | −$0.66 | −$1.10 | +29.0% | 7 |
| Current fiscal year (2026) | −$3.38 | −$3.67 | −$2.91 | −$3.53 | +4.3% | 7 |
| Next fiscal year (2027) | −$3.33 | −$4.15 | −$2.59 | −$3.38 | +1.6% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MLTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 12 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 13 |
| Next fiscal year (2027) | $19.0M | $0 | $40.7M | 0.0% | 13 |
MLTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MLTX revenue: reported and forecast
MLTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.92 | −$0.78 | −$0.78 | −$0.78 | −$0.78 | −15.5% | 6 up · 0 down |
| Current fiscal year (2026) | −$3.84 | −$3.33 | −$3.38 | −$3.38 | −$3.38 | −12.0% | 5 up · 1 down |
| Next fiscal year (2027) | −$3.43 | −$3.34 | −$3.33 | −$3.33 | −$3.33 | −3.0% | 5 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MLTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MLTX beat in 5 of 12.
What analysts expect from MLTX
15 analysts cover MoonLake Immunotherapeutics; their consensus rating is buy (4.13 on a 1–5 scale, where 5 is a strong buy). The average price target is $28.54, 198.8% above the latest close of $9.55. Analysts expect earnings of −$3.38 per share for 2026, +4.3% from a year earlier. For 2027 the average estimate is −$3.33 per share on revenue of $19.0 million. MoonLake Immunotherapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: MLTX income statement, MLTX key metrics, MLTX chart. See the MLTX stock overview for the latest quote and news.
MLTX forecast FAQ
What is MoonLake Immunotherapeutics's price target?
The average analyst price target for MoonLake Immunotherapeutics is $28.54, 198.8% above the latest close of $9.55.
Is MoonLake Immunotherapeutics a buy, hold or sell?
Of 15 analysts covering MoonLake Immunotherapeutics, 10 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 2 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is MoonLake Immunotherapeutics's EPS forecast?
Analysts forecast −$3.38 per share for 2026 (range −$3.67 to −$2.91); for 2027 the estimate is −$3.33.
When does MoonLake Immunotherapeutics report earnings?
MoonLake Immunotherapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.77.
Does MoonLake Immunotherapeutics usually beat earnings estimates?
MoonLake Immunotherapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.